D
Beam Therapeutics Inc. BEAM
$16.46 -$2.02-10.93%
Recommendation
Sell
Prev Close
$18.48
Volume
3,382,246
Avg Vol (90D)
1,555,716
Market Cap
$1.50B
Dividend & Yield
--
52-Week Range
$17.16 - $35.25
P/E (TTM)
--
EPS (TTM)
-$4.58
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Beam Therapeutics (NASDAQ:BEAM) Sets New 1-Year Low - Here's Why
4/3/2025 - Ticker Report
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 10.6% - Time to Sell?
4/1/2025 - MarketBeat
Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?
4/1/2025 - Yahoo! Finance: News
Beam Therapeutics (BEAM, $19.53) RSI Indicator left the oversold zone on March 31, 2025
4/1/2025 - Tickeron - Stocks
8 Best Gene-Editing Stocks to Buy
3/31/2025 - Insider Monkey
Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard
3/31/2025 - Invezz News
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics
3/31/2025 - Zacks Investment Research
11 Best Gene Therapy Stocks to Buy According to Analysts
3/30/2025 - Insider Monkey
Beam Therapeutics (NASDAQ:BEAM) Raised to Buy at Bank of America
3/29/2025 - MarketBeat
Beam Therapeutics (BEAM) Upgraded to Buy by Bank of America on Promising Data
3/29/2025 - GuruFocus
Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic Treatment Data
3/29/2025 - GuruFocus
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
3/28/2025 - Zacks Investment Research
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
3/28/2025 - Zacks Investment Research
Futures Slide, Gold Soars Ahead Of Inflation Data Amid Tariff Turmoil
3/28/2025 - Zero Hedge
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock
3/28/2025 - Benzinga
BIT Capital GmbH Invests $878,000 in Beam Therapeutics Inc. (NASDAQ:BEAM)
3/28/2025 - MarketBeat
Beam Therapeutics upgraded to Buy at BofA after BEAM-302 data
3/28/2025 - The Fly
BofA gets more bullish on Beam Therapeutics, upgrades shares
3/28/2025 - The Fly
FDA Clears Beam Therapeutics' (BEAM) Drug for Genetic Disease Treatment
3/27/2025 - GuruFocus
Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S.
3/27/2025 - Seeking Alpha - Healthcare
Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S.
3/27/2025 - SeekingAlpha.com: All News
Beam announces FDA clearance of BEAM-302 investigational new drug application
3/27/2025 - TipRanks Financial Blog
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
3/27/2025 - Globe Newswire
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound?
3/27/2025 - Zacks Investment Research
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 3.8% - Time to Sell?
3/26/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$63.52M
EBITDA (TTM)
-$393.64M
EBIT (TTM)
-$415.57M
Net Income (TTM)
-$376.74M
Balance Sheet
Total Assets (Q)
$1.10B
Total Debt (Q)
$161.43M
Total Liabilities (Q)
$370.28M
Book Value Per Share (Q)
$9.05
Cash Flow
Cash from Operations (TTM)
-$347.25M
Cash from Investing (TTM)
$185.01M
Cash from Financing (TTM)
$7.74M
Net Change in Cash (TTM)
-$154.50M
Filings
Filing Date
Tuesday, February 25, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
2.95
7-Day Total Return
-29.11%
30-Day Total Return
-50.33%
60-Day Total Return
-37.56%
90-Day Total Return
-32.79%
Year to Date Total Return
-33.36%
1-Year Total Return
-44.54%
2-Year Total Return
-45.37%
3-Year Total Return
-73.60%
5-Year Total Return
2.17%
52-week Low
Apr 02, 2025 - $17.16
52-week High
Feb 18, 2025 - $35.25
Valuation
Market Cap
$1.50B - Small Cap
Enterprise Value
$809.62M
Price/Sales (TTM)
24.10
Price/Book (Q)
2.04
Dividends and Shares
Shares Outstanding
82.82M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
beamtx.com
Phone Number
857 327 8775
Address
238 Main Street
Cambridge, MA 02142
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101... more
NASDAQ 04/03/2025 4:00PM Eastern Quotes delayed
Weiss Ratings